Celldex Therapeutics

Yahoo Finance • 13 days ago

Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch

* Celldex Therapeutics (CLDX [https://seekingalpha.com/symbol/CLDX]) priced [https://seekingalpha.com/pr/20460246-celldex-announces-pricing-of-300-million-public-offering-of-common-stock] an underwritten public offering of ~10.3M shares... Full story

Yahoo Finance • 13 days ago

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public... Full story

Yahoo Finance • 13 days ago

Celldex Therapeutics announces public offering of common stock

* Celldex Therapeutics (CLDX [https://seekingalpha.com/symbol/CLDX]) announced on Wednesday that it has commenced an underwritten public offering for the sale of shares of its common stock. * In addition, Celldex expects to grant the u... Full story

Yahoo Finance • 13 days ago

Celldex Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In... Full story

Yahoo Finance • 24 days ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 24 days ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 24 days ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 24 days ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • last month

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

- Late breaking Poster Presentation at AAAAI - - Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Cellde... Full story

Yahoo Finance • last month

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory

We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.'s share was trading at $30.82 as of February 25th.test, cancer,... Full story

Yahoo Finance • 2 months ago

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved quality of life and reduced disease impa... Full story

Yahoo Finance • 2 months ago

Celldex Therapeutics Stock Earns 88 RS Rating

On Thursday, Celldex Therapeutics stock received an upgrade to its Relative Strength (RS) Rating, from 63 to 88. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price ac... Full story

Yahoo Finance • 2 months ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE... Full story

Yahoo Finance • 2 months ago

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 o... Full story

Yahoo Finance • 4 months ago

Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc. (NASDAQ:CLDX) to $24 from $21 on December 17 and reaffirmed an E... Full story

Yahoo Finance • 4 months ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a larg... Full story

Yahoo Finance • 5 months ago

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and s... Full story

Yahoo Finance • 5 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30... Full story

Yahoo Finance • 5 months ago

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a nove... Full story

Yahoo Finance • 6 months ago

Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns

Barclays’ recent launch of coverage on Celldex Therapeutics (CLDX) assigned the stock an Underweight rating, drawing investor focus to both sector competition and questions about the safety profile of barzolvolimab. See our latest analysi... Full story